Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of combining a bispecific antibody targeting CEA (CEACAM5) on tumor cells and CD3 on T cells, NILK-2301, and a bispecific antibody targeting CEA on tumor cells and CD28 on T cells, NILK-3301.